Wednesday, March 7, 2012

Gilead deal takes hit as 2 more hepatitis C patients relapse

Two more hepatitis C patients relapsed after they stopped taking an experimental drug that was the keystone of Gilead Sciences Inc.’s recent $11 billion acquisition of Pharmasset Corp.
The news means that eight of 10 patients in the trial of the oral drug, called GS-7977, relapsed within four weeks of treatment, Reuters reported Tuesday from the Conference on Retroviruses and Opportunistic Infections.

No comments:

Post a Comment